Summary. Previous 
Introduction
Since early pregnancy factor (EPF) was first described as a pregnancy-associated substance, present in serum of mice within 6 h offertile mating (Morton et ai, 1976) , many groups have investigated aspects of its biological properties in a wide variety of species. While fewer have attempted to isolate the active agent, several reports on the purification of EPF-active substances have appeared to date. These include preparations from sera of pregnant ewes (Wilson et ai, 1983) , sheep placentae (Clarke et ai, 1987) , medium conditioned by oestrous mouse ovaries and oviducts stimulated with prolactin and medium conditioned by mouse embryos (Cavanagh, 1984) , medium conditioned by the human choriocarcinoma cell-line BeWo (Cavanagh, 1985) , and human preg¬ nancy serum (Mehta et ai, 1989) . There are insufficient data to speculate about the relationship of these substances to each other and thorough comparison must await the cloning of their respective genes. Nevertheless, we have undertaken the preliminary investigations below to clarify one of the more puzzling aspects of the biochemical properties of EPF described to date.
Several studies have suggested that EPF produced early in pregnancy differs from that pro¬ duced later in gestation. From investigations in the mouse, Morton et ai (1980) concluded that during the pre-and peri-implantation stage, the maternal oviduct and ovary each produce an inactive component, termed EPF-A and EPF-B respectively, which combine to produce EPF. These components have counterparts, produced by fractionation of early pregnancy serum with 40% saturated ammonium sulphate (Clarke et ai, 1980) ; the supernatant corresponds with EPF-A and the precipitate with EPF-B. More recent experiments in the rabbit have confirmed these results (Suoeka et ai, 1989) . In contrast, serum obtained later in gestation is not split into two inactive components by 40% ammonium sulphate (Wilson et ai, 1984) ; a single active species appears to be present, whose source is fetal (Morton et ai, 1982; Clarke & Wilson, 1982; Clarke et ai, 1987) .
Of the purified substances noted above, the material isolated from medium conditioned by mouse oviducts and ovaries (mEPF) is the only example of the 'early' form of EPF. Consistent with the studies above, it appears to consist of inactive components which in combination are active; the other substances apparently consist of a single active component. Nevertheless, studies in this laboratory on the EPF-active molecule isolated from BeWo-conditioned medium (hEPF), representative of the 'late' form of EPF, indicate that it is closely related to 'early' EPF (mEPF). An immunoabsorbent prepared from anti-mEPF could be used to purify hEPF (Cavanagh, 1985) while antibodies to hEPF, administered to mice on Days 1 and 2 of pregnancy, interrupt gestation in a significant number of cases (Athanasas-Platsis et ai, 1989) . However, hEPF is considerably more potent (approximate lowest active dose of hEPF = 50 fg/ml, mEPF = 100 pg/ml ; Cavanagh 1984 Cavanagh , 1985 in the bioassay for EPF, the rosette inhibition test (Morton et ai, 1974 (Morton et ai, , 1987 Rolfe et ai, 1984) . This suggests that an inhibitor(s) might be co-purifying with mEPF. If this is considered in conjunction with the bell-shaped dose-response curve which both molecules exhibit in the bio¬ assay (i.e. high as well as low concentrations give negative results; Cavanagh, 1984 Cavanagh, , 1985 (Rugh, 1968 (Morton el ai, 1974 (Morton el ai, , 1976 .
The assay was performed with spleen cells from male mice, rabbit anti-mouse lymphocyte serum and human red blood cells (RBC) (Rolfe et ai, 1984; Morton et ai, 1987) , with one batch of ALS used throughout. For each test, [1] [2] [3] [4] [5] [6] [7] [8] 107 freshly isolated spleen cells were incubated at 37°C for 0-5 h with 0-2 ml test sample. After incubation, the cells were washed twice in Hank's balanced salt solution, without calcium or magnesium (HBSS), reconstituted to 10 ml in HBSS and used to estimate the RIT of an ALS as described by Rolfe et ai (1984) . Positive Organ culture. For separate culture, ovaries and oviducts were removed separately from 6 superovulated mice within 20 h of hCG injection. Two groups of 6 ovaries were cultured in RPMI 1640 with the addition of prolactin and medium conditioned by mouse embryos, while 2 groups of 6 oviducts were each cultured in 5 ml RPMI 1640, as described previously (Cavanagh, 1984) . Conditioned medium, alone and in combination, was then tested in the rosette inhibition test over a range of dilutions using the protocol for serum described above.
For joint culture, ovaries and oviducts were removed as a unit from 80 superovulated mice within 20 h of hCG injection and cultured in RPMI 1640 with prolactin and medium conditioned by mouse embryos, as described previously (Cavanagh, 1984) . Conditioned medium was used for purification of mEPF.
Purification of mEPF. mEPF was purified from medium conditioned by ovaries and oviducts combined, following the method described by Cavanagh (1984) , with the following variations. A second generation immunoabsorbent was used in the initial step, prepared from 300 mg goat IgG raised against mEPF purified by the original method and coupled to CNBr-activated Sepharose 4B according to the manufacturer's instructions (Pharmacia-LKB). was omitted from the second electrofocusing step and, following the final gel-filtration step, half the preparation was subjected to reversed-phase HPLC (RP-HPLC) under conditions used for purification of hEPF (Cavanagh, 1985) . Briefly, trifluoroacetic acid (TFA; Sequenal grade, Pierce Chemical Company, IL, USA) was added to a final concen¬ tration of 01%, and, after passage through an 0-45 pm filter, the sample was applied to a C3 column (Ultrapore RPSC, 4-6 75 mm, 5 pm particle size, 30 nm pore size; Beckman Instruments, CA, USA) which had been equili¬ brated with 0-1 % TFA. The column was then eluted with a 2 min linear gradient to 25% isopropanol (HPLC grade; Mallinckrodt, KE, USA), followed by a 30 min linear gradient to 30% isopropanol, both containing 0-1% TFA. A flow rate of 1 ml/min was maintained throughout.
For high-performance gel permeation chromatography (GP-HPLC), samples were applied to a TSK G3000 SW column (7-5 600 mm) with TSK-GSWP precolumn (7-5 75 mm) (Pharmacia-LKB), through a 250 pi sample loop, using 0-1 M-sodium phosphate buffer pH 6-8 containing 0-1 % sodium dodecyl sulphate (SDS; BDH, Poole, UK) as equilibration and running buffer. A flow rate of 0-5 ml/min was maintained throughout.
Results

Ammonium sulphate studies
The earlier studies of Clarke et al. (1980) , which showed that 40% saturated ammonium sulphate could apparently split EPF activity in early pregnancy serum into two components, were repeated but tested over an extensive range of dilutions, as shown in Fig. 1(a) Since the original studies indicated that "EPF-A" was produced by the oviduct during oestrus as well as early pregnancy (Morton et ai, 1980) , the present studies were extended to include serum from mice in oestrus and dioestrus. As shown in Fig. 2(a) and (b), neither supernatant nor pellet fractions from either source were active when tested over a wide range of dilutions. In Fig. 2(a) it can be seen that 'dioestrous' supernatant has no effect on activity of either Day 2 or Day 10 precipitate (see Fig. la and b, respectively) in contrast with 'oestrous' supernatant ( Fig. 2b) which exhibits an inhibitory effect similar to that of Day 2 supernatant (see Fig. la) . The dose-response of the inhibitory effect of 'oestrous' supernatant on Day 2/10 precipitate is shown in Fig. 2(c) Fig. 3(a) . As was found with the original studies (Morton et ai, 1980) , when tested at low dilutions, neither medium conditioned by the ovary nor oviduct alone exhibit activity, but a combination of the two does. However, when the range of dilutions is extended, ovary-conditioned medium alone is found to be active. Medium conditioned by the oviduct shows no activity at any dilution tested but is able to reduce consider¬ ably the EPF titre of ovary-conditioned medium, suggesting that it is a source of the inhibitor(s) identified above. In Fig. 3(b) the dose-response of this inhibitory effect is shown with parallel curves again being generated, suggesting that mechanisms similar to those seen with serum (Figs 1 and 2) are operating. This is confirmed in Fig. 3 
HPLC studies
The RP-HPLC profile of mEPF is shown in Fig. 4 Fig. 4 ) and a recombinant of this and the inhibitory fraction separated by RP-HPLC (pool 5, Fig. 4) are shown in Fig. 5 . As was seen with serum and conditioned medium, the effect of the inhibitor is to induce a substantial shift in the dose-response curve indicating that the isolated substance(s) is acting in a manner similar to the inhibitory fractions of both serum-free conditioned medium (source material) and serum.
Since the apparent components in mEPF, as originally purified, were analysed by GP-HPLC in the presence of SDS (Cavanagh, 1984) , this technique was applied to the active and inhibitory fractions produced by RP-HPLC, along with an equivalent amount of the mEPF preparation before RP-HPLC. As shown in Fig. 6 , mEPF and the inhibitor(s) co-eluted, even under dissociat¬ ing conditions. In the original studies, SDS appeared to split EPF into three peptides, none of which had activity in the rosette inhibition test. When equal amounts of all three, but not of any two, were mixed, activity was again observed. However, peaks and combinations were tested at a single dilution. At that stage, no studies had been performed on BeWo conditioned medium and there was no reason to test beyond the range observed with ovary-oviduct conditioned medium. If the range of dilutions had been extended, the studies in Fig. 6 suggest that a positive result would have been obtained within the area of elution but, as originally tested, it was not until sufficient amounts of inhibitor had been added (i.e. all 3 peaks were mixed) that the EPF titre was reduced to the dilution tested. Nevertheless, while the breadth of the peaks in Figs 6(b) and (c) do suggest heterogeneity, they do not reproduce the original studies. Having established conditions for separation of the inhibitor(s) from EPF, it will be possible to determine whether the 3 peaks orig¬ inally seen form a complex or whether some were chance contaminants, subsequently eliminated by use of a more specific immunoabsorbent.
Discussion
The studies described above flow from insights into the mechanism of action of EPF in the rosette inhibition test, gained through attempts to isolate the active species. The assay is essentially nonquantitative and the RIT of a sample is not a reliable measure of EPF concentration. The assay can be used in a semi-quantitative manner by testing samples over a range of dilutions and determining Sample dilution (reciprocal) Fig. 1 , suggests that the evaluation procedures used by Bose et al. (1989) would almost certainly miss the most active fractions. It is probable that the activity shown by the isolated M, 14 000 substance reflects the presence of a very minor contaminant.
Nevertheless, when used with care, the rosette inhibition test is invaluable in resolving at least some of the complexity associated with EPF. In the studies above, it could determine that the differences previously observed between the so-called 'early* and 'late' forms of EPF are the result of modulation of the activity of EPF in the rosette inhibition test by a substance(s) present during oestrus and the early stages of gestation. The substance(s) has been termed an inhibitor because it substantially reduces the titre of EPF in the above assay. The two components thought to be present early in pregnancy can be understood therefore as EPF and inhibitor(s); EPF-B becomes EPF, EPF-A the inhibitor(s). Thus as pregnancy proceeds, it is not EPF that alters but rather the inhibitor which disappears from the circulation soon after implantation (see also Fig. 3 , Morton et ai, 1983;  Fig. 2 Fig. 4 ), while exhibiting no activity itself, is able to reduce this titre to the level observed before RP-HPLC. Although preliminary, these studies reveal that, when analysed by one of the highest resolution techniques currently available, mEPF ('early') and hEPF ('late') display significant similarities. Furthermore, by demonstrating that the regulatory and active components can be separated, they make it possible to study the biological significance of the regulatory substance(s).
The inhibitor(s) modifies the action of EPF on lymphocytes. In its presence, higher concentrations of EPF are required to stimulate the suppressor release by which the action of EPF in the rosette inhibition test and the delayed-type hypersensitivity reaction is mediated (Rolfe et ai, 1988 (Rolfe et ai, , 1989 ). The range ofconcentrations over which EPF is able to affect lymphocytes is thus extended, suggesting a possible biological function for the regulator. That this substance does have a role is reinforced by the observation that production of the inhibitor is under hormonal control, being produced by the oviduct during oestrus and early pregnancy (Morton et ai, 1980 ; see also Morton (1984) for an illustration of the effect of the oestrous cycle on EPF-A in serum). A larger Mr binding protein (or group of proteins; Mr > 100 000) also associates with EPF in serum during the pre-and periimplantation period. It appears to act as a storage protein for EPF and has been observed in mice (Clarke et ai, 1978) , sheep (Clarke et ai, 1980) , pigs (Morton et ai, 1983) and humans (Rolfe et ai, 1983) . EPF can be separated from the protein(s) by anion exchange chromatography (Clarke et ai, 1980) but its activity is not altered during this process. These results are in contrast with the properties of the inhibitory substance discussed above but, when taken together, suggest a mechanism of both coarse (storage/protein carrier) and fine (inhibitory protein carrier) regulation of EPF activity. An analogous situation has been described for control of insulin-like growth factors (IGFs). Large (Mr 150 000) and smaller (M, 35 000) binding proteins have been identified, with the former binding the majority of IGFs in serum and performing a storage function, while the latter is itself subject to hormonal control, which, in turn, closely regulates IGF function (Hall et ai, 1988) .
It may be that the co-purification of the inhibitory substance(s) with EPF is fortuitous and its effect in the rosette inhibition test is unrelated to EPF. Alternatively it may be an indication that, like many hormones and growth regulators, EPF activity in vitro and in vivo may be modulated by a complex balance of inhibitors and activators. Now that at least one source of a regulator is known and a technique established to separate it from EPF, more definitive studies on the relationship of the substances can begin.
